Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: An evolutionary alternative to the Warburg shift?

Neuro-Oncology

Volumn 13, Issue 12, 2011, Pages 1262-1264

  Scott, Jacob G ^a,d   Basanta, David ^a   Chinnaiyan, Prakash ^a   Canoll, Peter ^b   Swanson, Kristen R ^c   Anderson, Alexander R A ^a  

^a Radiation Oncology ^*  (United States)

^b Howard Hughes Medical Institute   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE; LACTIC ACID;

ANAEROBIC GLYCOLYSIS; GLIOMA; HUMAN; LETTER; MUTATION;

BRAIN NEOPLASMS; EVOLUTION, MOLECULAR; GLIOMA; GLUTARATES; GLYCOLYSIS; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; OXYGEN CONSUMPTION;

EID: 84856257331     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor083     Document Type: Letter

References (21)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807-1812.
2. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007.
3. Yan H, Parsons W, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
4. Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncology. 2011;12(1):83-91.
5. Zhao S, Lin Y, Jiang W, et al. Glioma-derived mutations in IDH1 dominantly inhibit ISH1 catalytic activity and induce HIF-1a. Science. 2009;324(5924):261-265.
6. Dang L,White D, Gross S, et al. Cancer-associated IDH1mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
7. Aghili M, Zahedi F, Rafiee E, et al. Hydroxyglutaric aciduria and malignant brain tumor: A case report and literature review. J Neurooncol. 2009;91(2):233-236.
8. Jin G, Reitman Z, Spasojevic I, et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP+-dependent isocitrate dehydrogenase mutations. PLoS ONE. 2011;6(2) e16812/journal.pone. 0016812.
9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891-899. (Pubitemid 39472955)
10. Gerlee P, Anderson ARA. A hybrid cellular automaton model of clonal evolution in cancer: The emergence of the glycolytic phenotype. J Theor Biology. 2008;250(4):705-722.
11. Smallbone K, Gatenby RA, Gillies RJ, et al. Metabolic changes during carcinogenesis: Potentional impact on invasiveness. J Theor Biol. 2007;244(4):703-713. (Pubitemid 46148971)
12. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
13. Shibata T, Kokubu A, Miyamoto M, et al. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol. 2011;178(3):1395-1402.
14. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334-343.
15. Basanta D, Simon M, Hatzikirou H, et al. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Proliferation. 2008;41(6):980-987.
16. Basanta D, Scott JG, Rockne R, et al. The role of IDH1 mutated tumor cells in secondary glioblastomas: An evolutionary game theoretical view. Phys Biol. 2011;8(1):015016.
17. Swanson KR, Alvord EC, Murray JD. A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif. 2000;33:317-329.
18. Morita T, Nagaki T, Fukuda I, et al. Clastogenicity of low pH to various cultured mammalian cells. Mutation Research. 1992;268(2):297-305.
19. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathol. 2010; 120(6):707-718.
20. Michelakis ED, Sutendra G, Dromparis L, et al. Metabolic modulation of glioblastoma with dichloroacetate. Science Translational Medicine. 2010;2(31):31ra34.
21. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells in with mutant IDH1. Cancer Research. 2010;70(22):8981-8987.